IL6 and hypertriglyceridemia: Because hypertriglyceridemia has previously been observed in patients who received siltuximab [5, 6] or other IL-6-inhibiting agents, such as tocilizumab [10, 11], and because siltuximab's mechanism of action involving IL-6 blockade may decrease platelet and neutrophil counts in patients, mean values over time for triglycerides, neutrophils, and platelets were recorded and are shown in Figure 2A–2C.